타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Cabazitaxel | Bicalutamide | ALECSAT |
Overview Company | AstraZeneca | OHSU Knight Cancer Institute | CytoVac A/S |
Overview Modality | ADC | ADC | CGT |
Overview Target | FRα | FRα | FRα |
Overview Indication | Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Cancer | Prostate Adenocarcinoma; Prostate Carcinoma | Hormone-refractory Prostate Cancer |
Overview Phase | PHASE_2 | PHASE_2 | PHASE_1 |
Overview Status | RECRUITING | ACTIVE | ACTIVE |
Overview Content status | Limited Data | Limited Data | Standard Database |
Overview Data Confidence | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · structured catalog |
Overview Development Signal | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | Investigational | Investigational | Investigational |
Technology Payload | DM1 in Oatp1a/b -/- was 1 | — | — |
Technology Linker | linker to produce three dual drug conjugates named dextran-GLA-CTX, dextran-ALA-CTX an | — | — |
MoA Mechanism | and global proteomic impact remain uncharacterized | target pharmacological interactions of the NSARAs studied (n = 4) including potent inhibition of γ-aminobutyric acid, GABA receptor | — |
MoA Biomarker | biomarker in patients | biomarker-based strategies to enable precise AR-targeted therapies in breast cancer | — |
Clinical Program phase | PHASE_2 | PHASE_2 | PHASE_1 |
Preclinical Animal (cat.) | — | Mouse, In vitro | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Cabazitaxel | Bicalutamide | ALECSAT |
Overview Company | AstraZeneca | OHSU Knight Cancer Institute | CytoVac A/S |
Overview Modality | ADC | ADC | CGT |
Overview Target | FRα | FRα | FRα |
Overview Indication | Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Cancer | Prostate Adenocarcinoma; Prostate Carcinoma | Hormone-refractory Prostate Cancer |
Overview Phase | PHASE_2 | PHASE_2 | PHASE_1 |
Overview Status | RECRUITING | ACTIVE | ACTIVE |
Overview Content status | Limited Data | Limited Data | Standard Database |
Overview Data Confidence | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · structured catalog |
Overview Development Signal | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | Investigational | Investigational | Investigational |
Technology Payload | DM1 in Oatp1a/b -/- was 1 | — | — |
Technology Linker | linker to produce three dual drug conjugates named dextran-GLA-CTX, dextran-ALA-CTX an | — | — |
MoA Mechanism | and global proteomic impact remain uncharacterized | target pharmacological interactions of the NSARAs studied (n = 4) including potent inhibition of γ-aminobutyric acid, GABA receptor | — |
MoA Biomarker | biomarker in patients | biomarker-based strategies to enable precise AR-targeted therapies in breast cancer | — |
Clinical Program phase | PHASE_2 | PHASE_2 | PHASE_1 |
Preclinical Animal (cat.) | — | Mouse, In vitro | — |
추천 비교
추천 비교